ライフサイエンスコーパス: PPS

1 PPS and heparin also decreased MMP-9 (P < 0.001) after t

2 PPS by itself, or CCh and NE in the absence of synaptic

3 PPS encodes MAX2/ORE9 (for MORE AXILLARY BRANCHES2/ORESA

4 PPS is a promising new therapy for alphavirus-induced ar

5 PPS is an excellent permeation enhancer which provides n

6 PPS was found to improve sensitivity in MALDI analyses o

7 PPS was injected intramuscularly weekly for 3 weeks.

8 PPS was tested for dose- and time-dependent cytotoxicity

9 for > or = 3 of 5 PPS [high] or for < or = 1 PPS [low]).

10 est response being to the PPS of serotype 3 (PPS 3).

11 (IgG > or = 1 microgram/mL for > or = 3 of 5 PPS [high] or for < or = 1 PPS [low]).

12 d with a 23-valent pneumococcal vaccine or a PPS 3-bovine serum albumin conjugate revealed that they

13 ulin loci (XenoMouse mice) vaccinated with a PPS-3-tetanus toxoid conjugate and their molecular genet

14 There is more ethical consensus about PPS than PSU.

15 ospice programs develop clear policies about PPS and PSU, including mechanisms for training and ensur

16 hCD19Tg mice lacked B-1b cells and adaptive PPS-specific antibody responses.

17 generated B-1b cells and protective adaptive PPS-specific antibody responses, whereas hCD19Tg mice la

18 nt jumping reads information across adjacent PPSs and implement it in the HapSeq program.

19 lities conditional on the states of adjacent PPSs.

20 These data suggest that in adults, PPS antibodies are sufficiently polymorphic to possess b

21 he plateau of SSSE and increased 24 hr after PPS.

22 All PPS-containing preparations induced IL-6 and TNF-alpha f

23 thy high-level responders (controls) for all PPS except for serotype 8.

24 as degraded more rapidly and that PB-145 and PPS inhibited the degradation of both proteins.

25 uctions in joint destruction with PB-145 and PPS treatments (P < 0.01) compared with buffer control.

26 rface in the animals treated with PB-145 and PPS.

27 At the population level, both PPS-6B and PPS-14 Abs expressed kappa and lambda chains, although 6

28 The avidities of PPS 6B- and PPS 23F-specific IgG2 antibodies ranged from 6 to 31 nM-

29 ntly higher than both unselected B cells and PPS-specific B cells.

30 duced calcium responses, PD-1 induction, and PPS-3-specific IgG3 responses and restored protection du

31 a negative correlation between HIV load and PPS response for the groups receiving HAART.

32 ] is also an independent predictor of OS and PPS in patients with radiologic progression.

33 puborectalis muscles between the PPS(+) and PPS(-) groups were compared.

34 s sequence to analyse the effect of VWS- and PPS-associated mutations in the DNA-binding domain of IR

35 ference between young and older adults, anti-PPS IgA or IgM antibodies were removed from immune sera

36 All anti-PPS levels were at or below prevaccination baselines by

37 Thus, functionally disparate anti-PPS antibodies can arise within individuals both by acti

38 In both age groups, anti-PPS IgA or IgM antibody levels were much lower than anti

39 enC resulted in a boosted secondary IgG anti-PPS response to S. pneumoniae.

40 IgG anti-PPS responses to PPS3, PPS14, and C-polysaccharide (C-PS

41 in IL-7Ralpha are severely impaired in anti-PPS responses and do not survive Streptococcus pneumonia

42 In order to determine the effects of anti-PPS IgA or IgM antibodies on the functional difference b

43 IgM antibody levels, the low levels of anti-PPS IgM antibody alone can explain the functional differ

44 enhanced both the primary and secondary anti-PPS responses in mice, especially the type 1 IgG isotype

45 Serum anti-PPS levels and antibodies specific for capsular types 3

46 gM antibody levels were much lower than anti-PPS IgG antibody levels.

47 In conclusion, even though anti-PPS IgG antibody levels are high compared with anti-PPS

48 antibody levels are high compared with anti-PPS IgM antibody levels, the low levels of anti-PPS IgM

49 rmal unfolding and the stabilization by APS, PPS-1 behaved like the unstable human PAPSS2 protein sug

50 Using multiplex bead arrays, PPS treatment was found to have significantly increased

51 rly post-CPB neither prevents nor attenuates PPS in children.

52 ed the development of SSSE when given before PPS.

53 independent and failed to generate a boosted PPS-specific secondary IgG response.

54 At the population level, both PPS-6B and PPS-14 Abs expressed kappa and lambda chains,

55 ion, the severity of which was alleviated by PPS therapy during RRV and CHIKV clinical disease.

56 The LTD induced by PPS in the presence of NE or CCh is of comparable magnit

57 SSSE induced by PPS is an advantageous animal model of refractory status

58 Induction of LTD by PPS was inhibited by NMDA receptor blockers (completely

59 Twelve hours after the induction of SE by PPS or 3 hr after pilocarpine administration, Gal-IR neu

60 At ambient temperature (25 degrees C), PPS-b-PDMA-b-PNIPAAM assembled into 66 +/- 32 nm micelle

61 Once the proteins are free from the cell, PPS also assists in protein solubilization by shielding

62 al variability (ITV) in brain regions coding PPS predicts individual differences of its boundary at t

63 methylprednisolone treatment may complicate PPS.

64 Complicated PPS--noncomplicated PPS plus hospital readmission +/- pe

65 rginally significant increase in complicated PPS (p = 0.05).

66 In conclusion, PPS alters extracellular matrix turnover through the ind

67 throughout IRF6 may cause VWS; in contrast, PPS-causing mutations are highly associated with the DNA

68 acrylamide)-block-(N-isopropylacrylami de)] (PPS-b-PDMA-b-PNIPAAM) that forms physically cross-linked

69 In total, 39/246 children (16%) developed PPS (noncomplicated: n = 30, complicated: n = 9).

70 and 23F Abs elicited in 15 adults following PPS vaccination.

71 g identified binding sites on PrP 23-106 for PPS, which include the octarepeat histidine and an N-ter

72 bs were found to have similar affinities for PPS-3 but different epitope specificities and CDR3 regio

73 V(H) was associated with lower affinity for PPS 14, a result suggesting that somatic mutation could

74 nd-alone version of the PPS and guidance for PPS users are being developed.

75 psular polysaccharide (PPS) are required for PPS-based vaccine-mediated protection against Streptococ

76 tion of anti-dsDNA IgA, but a major role for PPS-associated TLR2 agonists was also revealed.

77 analyses of seven Fab fragments specific for PPS serotype 6B, 14, or 23F.

78 all patients with WS undergoing therapy for PPS from 1984 to 1999 were reviewed.

79 ic geranyl(geranyl)diphosphate synthase [G(G)PPS] is involved in myrcene biosynthesis in hop trichome

80 , we also assessed peripersonal space, e.g., PPS, the area around the body used to act on nearby obje

81 The patient was also given PPS for a short period by peripheral infusion and there

82 o catalyzes depupylation, it was unclear how PPS function could be maintained without Dop and PafA ca

83 ears to be a general characteristic of human PPS-specific Ab repertoires, and we suggest that this pr

84 +/- 32 nm micelles comprising a hydrophobic PPS core and PNIPAAM on the outer corona.

85 s to identify some of the recent advances in PPS and to describe progress towards greater standardiza

86 proposed as a mechanism of Peters anomaly in PPS.

87 rget proteins is functionally compromised in PPS is unknown.

88 This was explained by >10-fold increases in PPS-specific immunoglobulin G (IgG) levels in Pneumovax-

89 purified and/or contaminating TLR ligands in PPS vaccine preparations.

90 molecular basis for the defects observed in PPS and potential targets that contribute to the patholo

91 observation that B3GLCT mutant phenotypes in PPS patients are less severe than embryonic lethal pheno

92 function of the disaccharide and its role in PPS remain unexplored.

93 ng of trunk-centered multisensory signals in PPS is of particular relevance for theoretical models an

94 bar respiratory centers during NREM sleep in PPS.

95 efficacy of specific pharmaceuticals used in PPS.

96 rs of a frameshift ABCG8 mutation increasing PPS levels in carriers by 50%.

97 rioception, body-related visual information, PPS, and embodiment) and argue that the fronto-parietal

98 Subcutaneously injected PPS-b-PDMA-b-PNIPAAM polymer solutions formed stable hyd

99 We describe a severe syndrome of isolated PPS in the adult that mimics chronic pulmonary thromboem

100 n, and management of 12 adults with isolated PPS, 17 to 51 years of age (mean, 36.2 +/- 9.7 years), w

101 erience with 12 adult patients with isolated PPS, half of whom had been previously diagnosed with chr

102 Fluorescently labeled PPS were used in FACSAria flow cytometry to characterize

103 The labeled PPS were capable of inhibiting binding of Ab to the nati

104 e oxidants were found to oxidize the micelle PPS core, making it more hydrophilic and triggering mice

105 eceiving 15 min and all animals after 30 min PPS developed SSSE that continued for hours.

106 ly decreased if injected 40 min after 30 min PPS, or 10 min after 60 min PPS.

107 zing animals, 10 min after the end of 30 min PPS, was significantly less effective than pretreatment

108 rting SSSE when injected 10 min after 30 min PPS.

109 Administration of diazepam after 60 min PPS was characterized by a further decrease of its effic

110 min after 30 min PPS, or 10 min after 60 min PPS.

111 timulation of the perforant path for 30 min (PPS) or by injection of lithium and pilocarpine, Gal-IR

112 Seven-minute PPS did not induce SSSE.

113 Thirty or sixty minutes PPS induced SSSE characterized by continuous behavioral

114 Reads that span multiple PPSs (jumping reads) can provide additional haplotype in

115 Polyphenylsilsesquioxane [PhSiO(1.5)](n) (PPS) and polyvinylsilsesquioxane [vinylSiO(1.5)](n) (PVS

116 Similarly, the native PPS were able to inhibit binding of PPS-specific B cells

117 le of inhibiting binding of Ab to the native PPS.

118 th cross-sectional width (spermine, 0.44 nm; PPS, 0.70 nm; PhTX 343, 0.75 nm).

119 Noncomplicated PPS--temperature >100.5 degrees F, pericardial friction

120 Complicated PPS--noncomplicated PPS plus hospital readmission +/- pericardiocentesis or

121 on of certain V(H)3 genes used in the normal PPS response.

122 The added advantage of PPS over conventional detergents such as sodium dodecyl

123 The avidities of PPS 6B- and PPS 23F-specific IgG2 antibodies ranged from

124 e native PPS were able to inhibit binding of PPS-specific B cells in a flow cytometric assay demonstr

125 te dissociation, modifying the boundaries of PPS, but leaving IPS distance unaltered.

126 d fMRI to capture the individual boundary of PPS and examine its neural underpinnings.

127 A major characteristic of the boundary of PPS in humans is the extremely high variability of its l

128 Direct characterization of PPS-specific B cells has not been performed.

129 d-type C57BL/6 (Wt) mice with a conjugate of PPS of serotype 3 and tetanus toxoid (PPS3-TT) and deter

130 Graphical display of PPS rules, a stand-alone version of the PPS and guidance

131 confirmed the reversibility of the effect of PPS.

132 However, neither the efficacy of PPS vaccines in immunocompromised individuals nor the ho

133 ns show high variability in the extension of PPS across individuals, but there is a lack of evidence

134 stimuli predicts the individual extension of PPS.

135 ens-cornea adhesion), which is a hallmark of PPS.

136 , and results in a striking 100% increase of PPS in carriers.

137 , we directly characterized the phenotype of PPS-specific B cells before and after vaccination with P

138 w cytometry to characterize the phenotype of PPS-specific B cells obtained from 18 young adults pre-

139 n infection and investigate the potential of PPS to treat disease.

140 nd transcellular pathways in the presence of PPS.

141 nown effect on the incidence and severity of PPS in children undergoing surgery with CPB.

142 eration, CPB time, incidence and severity of PPS.

143 Ten patients with clinical signs of PPS underwent polysomnographic recording for two consecu

144 TLR2 activity was distinct from that of PPS, in that it was phenol extractable.

145 he TLR2/4 antagonist, OxPAPC, at the time of PPS immunization completely blocked the production of an

146 ective data demonstrate the potential use of PPS-b-PDMA-b-PNIPAAM as an injectable, cyto-protective h

147 n was inhibited by the addition of PB-145 or PPS.

148 cted diversity was a feature common to other PPS specificities, we examined the light (L)-chain expre

149 ere was no inter-group difference in overall PPS incidence (p = 0.73).

150 t anti-pneumococcal capsular polysaccharide (PPS) antibody avidity can influence protective efficacy.

151 ies to pneumococcal capsular polysaccharide (PPS) are a critical component of vaccine-mediated immuni

152 ies to pneumococcal capsular polysaccharide (PPS) are required for PPS-based vaccine-mediated protect

153 Pneumococcal capsular polysaccharide (PPS) vaccines are less immunogenic in immunocompromised

154 ies to pneumococcal capsular polysaccharide (PPS), we studied the response of transgenic mice reconst

155 ies to pneumococcal capsular polysaccharide (PPS).

156 . pneumoniae type 3 capsular polysaccharide (PPS-3) and other strong TI-2 Ags were significantly impa

157 type 3 pneumococcal capsular polysaccharide (PPS-3) were generated from transgenic mice reconstituted

158 th the purified pneumococcal polysaccharide (PPS) has been a topic of debate.

159 By contrast, pneumococcal polysaccharide (PPS) immunization protected CD19(-/-) mice during lethal

160 ate that Abs to pneumococcal polysaccharide (PPS) serotypes 1 and 6B have limited clonal diversity.

161 Remarkably, pneumococcal polysaccharide (PPS) vaccination alone induced C4(-/-) mice to produce i

162 The current pneumococcal polysaccharide (PPS) vaccine is highly effective in young adults; howeve

163 o the 23-valent pneumococcal polysaccharide (PPS) vaccine, Pneumovax, such as children <2 y, the aspl

164 ibodies against pneumococcal polysaccharide (PPS), older adults had lower IgA and IgM antibody levels

165 ning to isolate pneumococcal polysaccharide (PPS)-specific Fab fragments from two vaccinated adults.

166 I) Ags, such as pneumococcal polysaccharide (PPS).

167 zed with native pneumococcal polysaccharide (PPS; Pneumovax23) or protein-PPS conjugate (Prevnar-13)

168 es to isolated pneumococcal polysaccharides (PPS) required TLR signaling in vivo.

169 ccination with pneumococcal polysaccharides (PPS).

170 d to determine whether pentosan polysulfate (PPS) inhibited proliferation and altered extracellular m

171 Pentosan polysulfate (PPS) is a glycan derivative that is orally bioavailable,

172 an (GAG)-like molecule pentosan polysulfate (PPS) to alleviate virus-induced arthritis.

173 thereof when bound to pentosan polysulfate (PPS).

174 ombin III (n = 9); and pentosan polysulfate (PPS; n = 7).

175 Dimethyl palmitoyl ammonio propanesulfonate (PPS), with excellent enhancement potential and minimal t

176 e key population found to produce protective PPS-specific antibody in both wild-type and CD19(-/-) mi

177 polysaccharide (PPS; Pneumovax23) or protein-PPS conjugate (Prevnar-13) vaccines.

178 gion genes to form pneumococcal capsular PS (PPS) 6B-specific paratopes.

179 ed a rapid primary pneumococcal capsular PS (PPS) response in mice that was dependent on CD4(+) T cel

180 A sequence analysis of a purified PPS-14-specific Ab having a single spectrotype gave unif

181 costs of HAIs and AMU in Singapore, repeated PPSs over the next decade will be useful to gauge progre

182 PD-1 blockade also selectively rescued PPS-3-specific IgG3 responses in CD21/35(-/-) mice.

183 Proportionate palliative sedation (PPS) uses the minimum amount of sedation necessary to re

184 atically, and pediatric procedural sedation (PPS) is increasingly performed by practitioners who are

185 s at individual potential polymorphic sites (PPSs).

186 Peripersonal space (PPS) is a multisensory and sensorimotor interface mediat

187 sorimotor interface, the peripersonal space (PPS), mediates every physical interaction between our bo

188 ry bodily stimuli within peripersonal space (PPS).

189 r for N-(4-hydroxyphenylpropanoyl)-spermine (PPS), and virtually absent for philanthotoxin 343 (PhTX

190 olated peripheral pulmonary artery stenosis (PPS) in the adult is rare and frequently unsuspected.

191 n dilation of peripheral pulmonary stenosis (PPS) in Williams syndrome (WS) is limited.

192 n and isolated peripheral pulmonic stenosis (PPS).

193 We analyzed plasma plant sterol (PPS) levels, a surrogate measure of cholesterol absorpti

194 ng SE induced by perforant path stimulation (PPS) at the ages of postnatal day 21 (P21) and P35 were

195 of intermittent perforant path stimulation (PPS) needed to induce self-sustaining status epilepticus

196 ief intermittent perforant path stimulation (PPS) was examined with regard to the effects of two conv

197 we discovered that paired-pulse stimulation (PPS) elicits a form of homosynaptic long-term depression

198 Here we demonstrate that random-structured PPS and PVS rearrange in the presence of catalytic amoun

199 yloxyethyl)pyridin-1-yl]propane-1-sulfonate (PPS).

200 sDNA IgA in C4(-/-) mice without suppressing PPS-specific Ab production.

201 onducted a national point prevalence survey (PPS) to determine the prevalence of healthcare-associate

202 ed to characterize postprogression survival (PPS) and assess with time-dependent covariates analysis

203 and severity ofpostpericardiotomy syndrome (PPS) in children after cardiac surgery with cardiopulmon

204 Peters Plus syndrome (PPS), a congenital disorder of glycosylation, results fr

205 ns in B3GLCT result in Peters plus syndrome (PPS), an autosomal recessive disorder characterized by e

206 pattern in patients with postpolio syndrome (PPS).

207 rome (VWS) and popliteal pterygium syndrome (PPS) are autosomal dominant disorders characterized by c

208 Popliteal pterygium syndrome (PPS; OMIM 119500) is a disorder with a similar orofacial

209 assessing paradoxical puborectalis syndrome (PPS) in patients with obstructive defecation syndrome (O

210 Its Pathway Pre & QJ1;diction System (PPS) is now an internationally recognized, open system f

211 he Medicare ESRD prospective payment system (PPS) and changes to dosing guidelines for erythropoiesis

212 quitin-like protein (Pup)-proteasome system (PPS), the bacterial equivalent of the eukaryotic ubiquit

213 Caco-2 studies revealed that PPS is an effective enhancer of macromolecular transport

214 Histological studies showed that PPS does not induce damage to the intestine.

215 In vivo studies in rats showed that PPS enhanced relative bioavailability of sCT by 45-fold

216 Our data suggest that PPS-3 consists of epitopes that can elicit both highly p

217 Our findings suggest that PPS-based vaccines can be effective in the setting of CD

218 ammation and joint swelling, suggesting that PPS is a promising candidate for drug repurposing for th

219 The PPS-b-PDMA-b-PNIPAAM micelles were preloaded with the mo

220 4 vs 0.27 +/- 0.17, P = 0.009) analysis, the PPS(+) patients displayed a lower absolute ADC differenc

221 ches of the puborectalis muscles between the PPS(+) and PPS(-) groups were compared.

222 In contrast, the PPS-specific B cells obtained postimmunization were pred

223 a lower absolute ADC difference than did the PPS(-) patients.

224 this prediction, we cloned and expressed the PPS-1 protein from the roundworm Caenorhabditis elegans

225 However, the PPS-responding B-cell population has not yet been identi

226 Likewise, the PPS-specific B cells obtained preimmunization consisted

227 y of PPS rules, a stand-alone version of the PPS and guidance for PPS users are being developed.

228 dividual differences in the extension of the PPS are predicted by variability of BOLD responses in th

229 arities resulting from implementation of the PPS or ESA label change.

230 ART may influence qualitative aspects of the PPS response by restoring expression of certain V(H)3 ge

231 nt with the proposed nutritional role of the PPS under starvation conditions.

232 The next decade should see the PPS, and the UM-BBD on which it is based, find increasin

233 died PS-specific responses, we find that the PPS 6B repertoire makes use of a diverse collection of h

234 These findings indicate that the PPS repertoire in the adult derives from memory B-cell p

235 ies, with the greatest response being to the PPS of serotype 3 (PPS 3).

236 tween July 2015 and February 2016, using the PPS methodology developed by the European Centre for Dis

237 bservations in healthy young volunteers, the PPS-responding B-cell population consisted primarily of

238 ) emissions were 28% and 17% higher with the PPS-M compared to the SMPS for LSHFO and MGO, respective

239 Consistent with this, PPS immunization induced a robust TI response in young I

240 n vitro opsonophagocytic activities of three PPS-specific mouse immunoglobulin G1 monoclonal antibodi

241 Thus, PPS is influenced by progression pattern and this is key

242 ctive, serotype-specific human antibodies to PPS 3, and they lend support to the proposal that these

243 ation immunoglobulin G2 (IgG2) antibodies to PPS serotypes 6B and 23F and examined the relationship b

244 Binding to PPS exposes a hydrophobic surface composed of aligned tr

245 ced fluorescence of PrP 23-106 when bound to PPS, consistent with the alignment of tryptophan side ch

246 pecificity, and efficacy for defined MAbs to PPS may identify antibody features that might be useful

247 sis of three monoclonal antibodies (MAbs) to PPS 3 generated from lymphoid cells from mice vaccinated

248 nt of SSSE when administered 10 min prior to PPS.

249 odel to study the human antibody response to PPS antigens.

250 anifested a V(H)3-(D12)-positive response to PPS, despite a similar IgG response in each group.

251 als to generate a V(H)3-positive response to PPS.

252 hin individual adults, serum Ab responses to PPS serotypes 6B, 14, and 23F derive from a small number

253 not adult mice are impaired in responses to PPS vaccination and to 4-hydroxy-3-nitrophenyl-acetyl-Fi

254 by the monoclonal antibody D12) responses to PPS were determined for first-time recipients of a 23-va

255 A single 526-kb haplotype mapped strongly to PPS levels, dramatically refining the mapped interval.

256 Although only one animal subjected to PPS at P21 developed chronic spontaneous seizures by sev

257 of observation, all the animals subjected to PPS at P35 became epileptic.

258 the hippocampus in P21 animals subjected to PPS, although extensive activation of hippocampal and ex

259 pal structures was seen in pups subjected to PPS-induced self-sustaining SE at P35 or LiPC SE at P21.

260 ith human immunoglobulin loci, XenoMouse, to PPS antigens in a pneumococcal vaccine.

261 mirror website of the UM-BBD, UM-BPT and UM-PPS is being developed at ETH Zurich to improve speed an

262 The new UM-PPS produces a multi-level prediction within an acceptab

263 The original UM-PPS predicted up to two prediction levels at a time.

264 y of Minnesota pathway prediction system (UM-PPS) recognizes functional groups in organic compounds t

265 d a rule-based Pathway Prediction System (UM-PPS) that predicts plausible pathways for microbial degr

266 Currently, the UM-PPS contains 260 biotransformation rules derived from re

267 The UM-PPS is freely available to all without registration.

268 As rules were added to the UM-PPS, more of them were triggered at each prediction step

269 ajority of PrP 23-106 remain disordered upon PPS binding, the octarepeat region adopts a repeating lo

270 -valent pneumococcal polysaccharide vaccine (PPS).

271 ned for first-time recipients of a 23-valent PPS vaccine, both receiving and not receiving HAART, and

272 The commercial 23-valent PPS vaccine, Pneumovax-23 also contained TLR ligands (TL

273 tinct mutations in 13 families affected with PPS.

274 Cells treated with PPS showed a decrease in cell number beginning 24 h afte

275 In the 5 patients treated with PPS survival was 16 months, 45 months, 84 months, 105 mo

276 ical findings in a case of vCJD treated with PPS.

277 aximum survival in patients not treated with PPS.

278 significantly increased after treatment with PPS (P < 0.001) and heparin (P < 0.05).

279 Treatment with PPS and heparin increased TIMP-1.

280 cell layer (P < 0.005) after treatment with PPS but not after treatment with heparin.

281 Furthermore, treatment with PPS reduced the severity of both RRV- and CHIKV-induced

282 These data suggest that vaccination with PPS may not be effective for patients during and after l

283 ic B cells before and after vaccination with PPS vaccine (PPV) in elderly adults, using fluorescently

284 o present, although less pronounced, without PPS.